Deferoxamine（Desferrioxamine B） is an iron chelator (binds Fe(III) and many other metal cations) that inhibits neuronopathy, may be used to modify the reduction of iron accumulation and deposition in tissues, and may improve neurological dysfunction by inhibiting ferroptosis and neuroinflammation following traumatic brain injury.Desferrioxamin-B has antioxidant, antiproliferative, Deferoxamine has antioxidant, antiproliferative, and antitumor activities, and can induce HIF-1α production, apoptosis and autophagy in cancer cells.Desferrioxamin-B can be used in the treatment of acute iron toxicity and COVID-19 related diseases.

Deferoxamine（1 mM；16小时或4周）在缺氧和高血糖条件下改善HIF-1α功能，并且在MEF细胞中降低ROS水平。[1] Deferoxamine mesylate（100 μM；24小时）提高InsR表达和活性，并诱导p-Akt/total Akt/PKB水平增加。[2] Deferoxamine（5、10、25、50、100 μM；7或9天）抑制肿瘤相关MSCs和骨髓MSCs的增殖。[3] Deferoxamine（5、10、25、50、100 μM；7天）诱导间充质干细胞凋亡。[3] Deferoxamine（10 μM；3天）影响间充质干细胞粘附蛋白表达。[3] Deferoxamine（100 μM；24小时）在SH-SY5Y细胞中诱导由HIF-1α水平介导的自噬。[4]

Deferoxamine（6.57 μg/只老鼠；滴注；每日一次，连续21天）能促进老年或糖尿病小鼠的伤口愈合并增加新血管生成。[1] Deferoxamine（200 mg/kg；腹腔注射；每日一次，连续两周）能够稳定HIF-1α并增加葡萄糖摄取，提升肝脏InsR表达及体内信号传导。[2]